The Astellas dermatology portfolio consists of prescription and over-the-counter products, including Protopic, Locoid and Locobase, and Zineryt to treat eczema, acne and skin infections. The transaction, which is
The technology targets effects of leukotriene B4 (LTB4) for modulating inflammation and immune response in the lung, providing a potential therapeutic approach to treat PAH. Eiger chief medical
Preliminary studies have demonstrated that PraediCareDx can be used to find AML patients who respond to alvocidib. Tolero is currently starting a randomized Phase II biomarker study in
Bullous pemphigoid is known to be associated with increased eotaxin-1 levels in serum and blister fluids. Immune recently started a Phase IIa open label clinical trial in bullous
GSK will increase potential milestone payments to Avalon Ventures from $40m to $50m for each biotech formed. The companies have also formed the seventh out of ten biotechs
The company completed negotiations to operate a significant proportion of the 70-acre Charnwood Campus in Loughborough, England, UK. Almac will occupy the formulation development and analytical testing plants
Rizaport, 5 mg and 10 mg, is an oral thin film formulation of rizatriptan benzoate. It is being developed by RedHill Biopharma and IntelGenx. It is the first
Belgium-based Janssen will have an exclusive right to develop and commercialize oxyntomodulin-based therapies including HM12525A outside China and South Korea. As per the deal, Janssen will make an
Xtampza ER is an extended-release, oral formulation of oxycodone, in development to manage pain severe enough for daily, long-term opioid treatment and for which alternative treatment options are
Sulfatinib inhibits the tyrosine kinase activity related with the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth receptor (FGFR), which plays a role in tumour growth. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.